Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 i

EQS-News: Formycon AG / Key word(s): Study results/StudyAflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study 06.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // February 6, 2023Aflibercept B...

Related Keywords

Munich ,Bayern ,Germany ,United States ,Australia ,Japan ,Canada ,United Kingdom ,America ,British ,Aflibercept Biosimilar ,Andreas Seidl ,Klinge Biopharma Gmb ,Regeneron Pharmaceuticals Inc ,Corporate Communications ,Coherus Biosciences Inc ,Drug Administration ,Distribution Services ,Teva Pharmaceutical Industries Ltd ,Klinge Biopharma Gmbh ,Coherus Biosciences ,Regeneron Pharmaceuticals ,Teva Pharmaceutical Industries ,Manager Corporate Communications ,British Journal ,Corporate News ,Regulatory Announcements ,